The National Institute for Health and Care Excellence has recommended sparsentan (Filspari, Vifor Pharma) for treating primary immunoglobulin A nephropathy in adults. The recommendation reverses NICE’s February decision to reject NHS funding for the drug. The regulator had previously said available evidence did not demonstrate value for money. The manufacturer provided additional analyses and agreed to … Read more
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, MD: Hello. I’m Dr Carol Wysham. Welcome to season 3 of the Medscape InDiscussion Type 2 Diabetes podcast series. Today, we’ll discuss chronic kidney … Read more
TOPLINE: Children exposed to maternal preeclampsia and born at term (37 weeks or more) were 26% more likely to develop kidney disease in the first year of life than those not exposed. They also faced notably high risks for chronic, unspecified, and diabetic kidney diseases as they grew older, particularly at or after 25 years … Read more
TOPLINE: Pentoxifylline, an anti–tumor necrosis factor alpha agent, did not improve survival outcomes in patients with severe alcohol-associated hepatitis complicated by acute kidney injury (AKI). METHODOLOGY: Severe alcohol-associated hepatitis is a life-threatening condition with corticosteroid treatment as the only therapy demonstrating short-term benefits, leading to the investigation of potential alternative therapies, such as pentoxifylline, particularly … Read more
Sotagliflozin Shows Promise for Diabetes Management,Despite FDA Hurdles New research presented at the American Association of clinical Endocrinology (AACE) Annual Meeting 2025 suggests that sotagliflozin (Inpefa) can lower A1C levels and reduce body weight in individuals wiht type 2 diabetes. However, the benefits appear to be less pronounced in patients with moderate-to-severe chronic kidney disease … Read more
TOPLINE: A substantial proportion of patients admitted to hospitals in Italy experienced acute kidney injury (AKI), which was associated with worsened in-hospital mortality outcomes, longer hospital stays, and more frequent admissions to intensive care units (ICUs). METHODOLOGY: Researchers conducted a retrospective observational study to examine the incidence of AKI in two Italian university hospitals from … Read more
TOPLINE: Systematic home-based screening for albuminuria in primary care identified previously undiagnosed risk for chronic kidney disease (CKD), with greater participation among individuals invited by general practitioners (GPs). Overall, 8.7% of GP-invited participants had confirmed increased albuminuria, with 40.6% of them being newly diagnosed. METHODOLOGY: Researchers conducted a cross-sectional screening study to evaluate the effectiveness … Read more
BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental glomerulosclerosis (FSGS) compared with the angiotensin II receptor blocker (ARB) irbesartan, a new post-hoc analysis of the phase 3 DUPLEX trial shows. “Dual endothelin angiotensin receptor blockade with sparsentan led to partial or complete … Read more
With efforts underway to expand access to the kidney transplant waiting list to more patients, including many with end-stage kidney disease (ESKD), new research underscored the corresponding significant increase in the number of donor organs needed to prevent increased waiting periods for patients. “We found that expanding the transplant waiting list would result in longer … Read more
Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and cardiovascular risk reduction are among the new CKD management recommendations from the Kidney Disease: Improving Global Outcomes (KDIGO) organization. “The last CKD guideline was published in 2012, and there have been so … Read more